{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:31:31Z","timestamp":1787027491642,"version":"build-2736575974"},"reference-count":111,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antioxidants"],"abstract":"<jats:p>Peyronie\u2019s disease (PD) is a chronic disease characterized by the development of fibrous tissue in the tunica albuginea of the penile corpora cavernosa that causes penile deformity. The precise cause of PD is not completely understood, but it is generally believed to be initiated by a specific injury in the affected area. Research has consistently shown that oxidative stress (OS) is a key player in PD. Pentoxifylline (PTX) is a synthetic derivative of methylxanthine that was initially used for the management of peripheral vascular disease. PTX has also been used in humans for several inflammatory and fibrotic conditions, including PD. PTX has several mechanisms of action, including antioxidant, antifibrotic, anti-inflammatory, and vasorelaxant. This article aims to verify, after a review of the literature regarding the use of PTX in PD, whether this substance is really able to cure PD. We conducted research by consulting the scientific literature on the topic. Results: After examining 39 articles, we considered 20 articles eligible for our narrative review, including a single randomized controlled clinical study, six clinical studies with a control group, a single uncontrolled clinical study, eight case report studies, and four systematic review articles. Conclusions: Although the systematic review articles selected in this paper showed no consistent evidence regarding the efficacy of PTX, in our opinion, the clinical studies we have analyzed undoubtedly demonstrate that PTX is able to combat PD, thanks to its ability to interfere with the pathogenic mechanisms of the disease. However, we believe that further new randomized controlled trials are necessary to more clearly demonstrate the effectiveness of PTX in the treatment of PD.<\/jats:p>","DOI":"10.3390\/antiox14020208","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T03:41:57Z","timestamp":1739331717000},"page":"208","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Oxidative Mechanism of Peyronie\u2019s Disease and Effectiveness of Pentoxifylline in the Therapeutic Management: A Narrative Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7312-1514","authenticated-orcid":false,"given":"Gianni","family":"Paulis","sequence":"first","affiliation":[{"name":"Department of Urology and Andrology, Peyronie\u2019s Care Center, Castelfidardo Clinical Analysis Center, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Paulis","sequence":"additional","affiliation":[{"name":"Bambino Gesu\u2019 Children\u2019s Hospital, IRCCS [Istituto di Ricovero e Cura a Carattere Scientifico], 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ajmg.1320120213","article-title":"Peyronie\u2019s disease: A newly recognized autosomal-dominant trait","volume":"12","author":"Bias","year":"1982","journal-title":"Am. J. Med. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.sxmr.2015.10.002","article-title":"The Genetic Basis of Peyronie Disease: A Review","volume":"4","author":"Herati","year":"2016","journal-title":"Sex. Med. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000282566","article-title":"HLA antigens in Peyronie\u2019s disease","volume":"52","author":"Rompel","year":"1994","journal-title":"Urol. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/j.1743-6109.2012.02704.x","article-title":"WNT2 Locus Is Involved in Genetic Susceptibility of Peyronie\u2019s Disease","volume":"9","author":"Dolmans","year":"2012","journal-title":"J. Sex. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1464-4096.2001.02436.x","article-title":"The prevalence of Peyronie\u2019s disease: Results of a large survey","volume":"88","author":"Schwarzer","year":"2001","journal-title":"BJU Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.ijir.3900727","article-title":"Prevalence of Peyronie\u2019s disease in men over 50-y-old from Southern Brazil","volume":"13","author":"Rhoden","year":"2001","journal-title":"Int. J. Impot. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"282503","DOI":"10.1155\/2011\/282503","article-title":"A Population-Based Study of Peyronie\u2019s Disease: Prevalence and Treatment Patterns in the United States","volume":"2011","author":"DiBenedetti","year":"2011","journal-title":"Adv. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1111\/j.1743-6109.2012.02868.x","article-title":"The prevalence of Peyronie\u2019s disease in Japan: A study in men undergoing maintenance hemodialysis and routine health checks","volume":"9","author":"Shiraishi","year":"2012","journal-title":"J. Sex. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Stuntz, M., Perlaky, A., des Vignes, F., Kyriakides, T., and Glass, D. (2016). The Prevalence of Peyronie\u2019s Disease in the United States: A Population-Based Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150157"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/j.1939-4640.2000.tb03387.x","article-title":"Peyronie\u2019s disease: Etiology, medical, and surgical therapy","volume":"21","author":"Hellstrom","year":"2000","journal-title":"J. Androl."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0022-5347(01)65370-9","article-title":"Sexual dysfunction in Peyronie\u2019s disease: An analysis of 222 patients without previous local plaque therapy","volume":"157","author":"Weidner","year":"1997","journal-title":"J. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1743-6109.2008.00895.x","article-title":"The Chronology of Depression and Distress in Men with Peyronie\u2019s Disease","volume":"5","author":"Nelson","year":"2008","journal-title":"J. Sex. Med."},{"key":"ref_13","first-page":"95","article-title":"Prevalence, psychological impact, and risk factors of erectile dysfunction in patients with Peyronie\u2019s disease: A retrospective analysis of 309 cases","volume":"8","author":"Paulis","year":"2016","journal-title":"Res. Rep. Urol."},{"key":"ref_14","first-page":"e499","article-title":"Mp33-12 Prevalence of Peyronie\u2019s disease and its psychosexual impact in the chinese population: A large cohort population-based cross-sectional study","volume":"203","author":"Wong","year":"2020","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/JU.0000000000001426","article-title":"Mental Disorders in Peyronie\u2019s Disease: A Swedish Cohort Study of 3.5 Million Men","volume":"205","author":"Henningsohn","year":"2021","journal-title":"J. Urol."},{"key":"ref_16","first-page":"355","article-title":"Peyronie\u2019s disease: Pathophysiology","volume":"370","author":"Devine","year":"1991","journal-title":"Prog. Clin. Biol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-5347(01)65361-8","article-title":"Proposal: Trauma as the cause of the Peyronie\u2019s lesion","volume":"157","author":"Devine","year":"1997","journal-title":"J. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0022-5347(01)64222-8","article-title":"Penile trauma: An etiologic factor in Peyronie\u2019s disease and erectile dysfunction","volume":"158","author":"Jarow","year":"1997","journal-title":"J. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5534\/wjmh.2013.31.1.1","article-title":"Surgical Management for Peyronie\u2019s Disease","volume":"31","author":"Segal","year":"2013","journal-title":"World J. Mens Health"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.aju.2013.06.006","article-title":"The pathophysiology of Peyronie\u2019s disease","volume":"11","author":"Salabas","year":"2013","journal-title":"Arab. J. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4653512","DOI":"10.1155\/2017\/4653512","article-title":"Recent Pathophysiological Aspects of Peyronie\u2019s Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatment-Literature Review","volume":"2017","author":"Paulis","year":"2017","journal-title":"Adv. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Paulis, G., De Giorgio, G., and Paulis, L. (2022). Role of Oxidative Stress in Peyronie\u2019s Disease: Biochemical Evidence and Experiences of Treatment with Antioxidants. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415969"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1464-410X.1997.26511.x","article-title":"Structural alterations in the tunica albuginea of the penis: Impact of Peyronie\u2019s disease, ageing and impotence","volume":"79","author":"Akkus","year":"1997","journal-title":"Br. J. Urol."},{"key":"ref_24","first-page":"722","article-title":"Diagnosis and Management of Peyronie Disease","volume":"Volume 1","author":"Wein","year":"2015","journal-title":"Campbell-Walsh Urology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/ijcp.12129","article-title":"Understanding the course of Peyronie\u2019s disease","volume":"67","author":"Garaffa","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1111\/jsm.12334","article-title":"Peyronie\u2019s disease plaque calcification--prevalence, time to identification, and development of a new grading classification","volume":"10","author":"Levine","year":"2013","journal-title":"J. Sex. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jsxm.2016.04.062","article-title":"Evidence-based management guidelines on Peyronie\u2019s disease","volume":"13","author":"Chung","year":"2016","journal-title":"J. Sex. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.eururo.2006.02.059","article-title":"A Critical Analysis of Nonsurgical Treatment of Peyronie\u2019s Disease","volume":"49","author":"Hauck","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01850.x","article-title":"The management of Peyronie\u2019s disease: Evidence-based 2010 guidelines","volume":"7","author":"Ralph","year":"2010","journal-title":"J. Sex. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s11255-015-1074-1","article-title":"Intralesional hyaluronic acid: An innovative treatment for Peyronie\u2019s disease","volume":"47","author":"Gennaro","year":"2015","journal-title":"Int. Urol. Nephrol."},{"key":"ref_31","first-page":"e83","article-title":"Intralesional Injection of Hyaluronic Acid in Patients Affected With Peyronie\u2019s Disease: Preliminary Results From a Prospective, Multicenter, Pilot Study","volume":"4","author":"Zucchi","year":"2016","journal-title":"Sex. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jsxm.2017.08.008","article-title":"Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie\u2019s disease","volume":"14","author":"Nguyen","year":"2017","journal-title":"J. Sex. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4103\/aja202371","article-title":"Intraplaque injections of hyaluronic acid for the treatment of stable-phase Peyronie\u2019s disease: A retrospective single-center experience","volume":"26","author":"Cilio","year":"2024","journal-title":"Asian J. Androl."},{"key":"ref_34","first-page":"39","article-title":"Peyronie\u2019s disease: Contemporary review of non-surgical treatment","volume":"2","author":"Levine","year":"2013","journal-title":"Transl. Androl. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2605.2011.01219.x","article-title":"Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie\u2019s disease: A study of 151 cases","volume":"35","author":"Paulis","year":"2012","journal-title":"Int. J. Androl."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2174\/0929867043365396","article-title":"Potential Therapeutic Effect of Antioxidant Therapy in Shock and Inflammation","volume":"11","author":"Cuzzocrea","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7432797","DOI":"10.1155\/2016\/7432797","article-title":"Oxidative Stress and Inflammation: What Polyphenols Can Do for Us?","volume":"2016","author":"Hussain","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_38","unstructured":"Roy, S., Bagchi, D., and Raychaudhuri, S.P. (2013). ROS Mediated Oxidative Stress as a Source of Inflammation. Chronic Inflammation: Molecular Pathophysiology, Nutritional and Therapeutic Interventions, CRC Press."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Huang, C., and Zhang, Y. (2021). Stress and Inflammation. Oxidative Stress. Human Diseases and Medicine, Springer Nature. [1st ed.].","DOI":"10.1007\/978-981-16-0522-2"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Camps, J. (2014). Introduction: Oxidation and Inflammation, A Molecular Link Between Non-communicable Diseases. Oxidative Stress and Inflammation in Non-Communicable Diseases\u2014Molecular Mechanisms and Perspectives in Therapeutics, Springer International.","DOI":"10.1007\/978-3-319-07320-0"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/niox.2001.0421","article-title":"Antifibrotic role of inducible nitric oxide synthase","volume":"6","author":"Ferrini","year":"2002","journal-title":"Nitric Oxide"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.ijir.3900880","article-title":"Role of oxidative stress and antioxidants in Peyronie\u2019s disease","volume":"14","author":"Sikka","year":"2002","journal-title":"Int. J. Impot. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/sj.ijir.3900873","article-title":"Gene expression in Peyronie\u2019s disease","volume":"14","author":"Magee","year":"2002","journal-title":"Int. J. Impot. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/ncpuro0201","article-title":"Mechanisms of Disease: New insights into the cellular and molecular pathology of Peyronie\u2019s disease","volume":"2","author":"Rajfer","year":"2005","journal-title":"Nat. Clin. Pract. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1095\/biolreprod.104.030833","article-title":"Gene Transfer of Inducible Nitric Oxide Synthase Complementary DNA Regresses the Fibrotic Plaque in an Animal Model of Peyronie\u2019s Disease1","volume":"71","author":"Davila","year":"2004","journal-title":"Biol. Reprod."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1095\/biolreprod.105.041038","article-title":"Evidence That Osteogenic Progenitor Cells in the Human Tunica Albuginea May Originate from Stem Cells: Implications for Peyronie Disease1","volume":"73","author":"Vernet","year":"2005","journal-title":"Biol. Reprod."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.ju.0000053800.62741.fe","article-title":"Peyronie\u2019s disease: A review","volume":"169","author":"Gholami","year":"2003","journal-title":"J. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.niox.2003.12.002","article-title":"L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie\u2019s fibrotic plaque and related fibroblast cultures","volume":"9","author":"Valente","year":"2003","journal-title":"Nitric Oxide"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.ijir.3900872","article-title":"Implications of nitric oxide synthase isoforms in the pathophysiology of Peyronie\u2019s disease","volume":"14","author":"Bivalacqua","year":"2002","journal-title":"Int. J. Impot. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/187152812798889321","article-title":"Inflammatory mechanisms and oxidative stress in Peyronie\u2019s disease: Therapeutic \u201crationale\u201d and related emerging treatment strategies","volume":"11","author":"Paulis","year":"2012","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cotox.2017.11.002","article-title":"NF-\u03baB in Oxidative Stress","volume":"7","author":"Lingappan","year":"2018","journal-title":"Curr. Opin. Toxicol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2164\/jandrol.05136","article-title":"Role of Oxidative Stress in the Pathophysiological Mechanism of Erectile Dysfunction","volume":"27","author":"Agarwal","year":"2006","journal-title":"J. Androl."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/ars.2012.5149","article-title":"Reactive Oxygen Species in Inflammation and Tissue Injury","volume":"20","author":"Mittal","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2147\/JIR.S275595","article-title":"Reactive Oxygen Species: Drivers of Physiological and Pathological Processes","volume":"13","author":"Checa","year":"2020","journal-title":"J. Inflamm. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1345\/aph.1E186","article-title":"Role of pentoxifylline and vitamin E in attenuation of radiation-induced fibrosis","volume":"39","author":"Chiao","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1200\/JCO.2005.02.4729","article-title":"Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis","volume":"23","author":"Delanian","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.radonc.2005.09.014","article-title":"Pentoxifylline and vitamin E combination for superficial radiation-induced fibrosis: A phase II clinical trial","volume":"77","author":"Haddad","year":"2005","journal-title":"Radiother. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/j.1572-0241.2004.40064.x","article-title":"A pilot trial of pentoxifylline in nonalcoholic steatohepatitis","volume":"99","author":"Adams","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ncpuro0409","article-title":"Treatment of Peyronie\u2019s disease with oral pentoxifylline","volume":"3","author":"Brant","year":"2006","journal-title":"Nat. Clin. Pract. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/0306-3623(93)90218-M","article-title":"Antiplatelet effect of pentoxifylline in human whole blood","volume":"24","author":"Romero","year":"1993","journal-title":"Gen. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF02790131","article-title":"Pentoxifylline. A hydroxyl radical scavenger","volume":"47","author":"Freitas","year":"1995","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1468-1331.2000.00116.x","article-title":"Effects of the non-selective phosphodiesterase inhibitor pentoxifylline on regional cerebral blood flow and large arteries in healthy subjects","volume":"7","author":"Kruuse","year":"2000","journal-title":"Eur. J. Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1124\/mol.64.4.811","article-title":"Pentoxifylline Inhibits Platelet-Derived Growth Factor-Stimulated Cyclin D1 Expression in Mesangial Cells by Blocking Akt Membrane Translocation","volume":"64","author":"Lin","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"ref_64","first-page":"427","article-title":"Pentoxifylline inhibits endotoxin-induced NF-kappa B activation and associated production of proinflammatory cytokines","volume":"34","author":"Ji","year":"2004","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3109\/08923970903183557","article-title":"Pentoxifylline modulates p47phox activation and downregulates neutrophil oxidative burst through PKA-dependent and -independent mechanisms","volume":"32","author":"Costantini","year":"2009","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1111\/j.1743-6109.2010.01790.x","article-title":"Pentoxifylline Attenuates Transforming Growth Factor-\u03b21-Stimulated Collagen Deposition and Elastogenesis in Human Tunica Albuginea-Derived Fibroblasts Part 1: Impact on Extracellular Matrix","volume":"7","author":"Shindel","year":"2010","journal-title":"J. Sex. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.yexmp.2014.05.009","article-title":"Pentoxifylline attenuates nitrogen mustard-induced acute lung injury, oxidative stress and inflammation","volume":"97","author":"Sunil","year":"2014","journal-title":"Exp. Mol. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11010-018-3438-1","article-title":"Potential therapeutic roles of 10-dehydrogingerdione and\/or pentoxifylline against calcium deposition in aortic tissues of high dietary cholesterol-fed rabbits","volume":"453","author":"Elseweidy","year":"2019","journal-title":"Mol. Cell. Biochem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41420-019-0225-z","article-title":"Natural and non-natural antioxidative compounds: Potential candidates for treatment of vascular calcification","volume":"5","author":"Chao","year":"2019","journal-title":"Cell Death Discov."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","article-title":"Peyronie\u2019s disease: AUA guideline","volume":"194","author":"Nehra","year":"2015","journal-title":"J. Urol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jsxm.2020.11.013","article-title":"Comparing and Contrasting Peyronie\u2019s Disease Guidelines: Points of Consensus and Deviation","volume":"18","author":"Manka","year":"2021","journal-title":"J. Sex. Med."},{"key":"ref_72","unstructured":"Salonia, A., Bettocchi, C., Capogrosso, P., Carvalho, J., Corona, G., Dinkelman-Smit, M., Hatzichristodoulou, G., Jones, T.H., Kadioglu, A., and Martinez-Salamanca, J.I. (2025, February 05). EAU (2024) Guidelines on Sexual and Reproductive Health. Available online: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2024_2024-05-23-101205_nmbi.pdf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/aja.2010.117","article-title":"Pentoxifylline treatment and penile calcifications in men with Peyronie\u2019s disease","volume":"13","author":"Smith","year":"2011","journal-title":"Asian J. Androl."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1743-6109.2011.02519.x","article-title":"Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie\u2019s disease","volume":"9","author":"Abern","year":"2012","journal-title":"J. Sex. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4081\/aiua.2013.1.36","article-title":"Peyronie\u2019s disease: A \u201ctriple oxygenant therapy\u201d","volume":"85","author":"Ciociola","year":"2013","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4081\/aiua.2014.3.237","article-title":"Efficacy of pentoxifylline in Peyronie\u2019s disease: Clinical case of a young man","volume":"86","author":"Ughi","year":"2014","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.5539\/gjhs.v6n7p23","article-title":"Evaluation of verapamil efficacy in Peyronie\u2019s disease comparing with pentoxifylline","volume":"6","author":"Alizadeh","year":"2014","journal-title":"Glob. J. Health Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5410\/wjcu.v3.i1.31","article-title":"Systematic review of the non surgical management of Peyronie\u2019s disease","volume":"3","author":"Verze","year":"2014","journal-title":"World J. Clin. Urol."},{"key":"ref_79","first-page":"1","article-title":"Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie\u2019s disease: A case-control study","volume":"8","author":"Paulis","year":"2015","journal-title":"Res. Rep. Urol."},{"key":"ref_80","first-page":"129","article-title":"Rationale of combination therapy with antioxidants in medical management of Peyronie\u2019s disease: Results of clinical application","volume":"9","author":"Paulis","year":"2017","journal-title":"Res. Rep. Urol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.esxm.2019.07.003","article-title":"Evaluation of Oral Pentoxifylline, Colchicine, and Penile Traction for the Management of Peyronie\u2019s Disease","volume":"7","author":"Ibrahim","year":"2019","journal-title":"Sex. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.acuro.2018.08.005","article-title":"Ten-year experience with multimodal treatment for acute phase Peyronie\u2019s disease: A real life clinical report. Diez a\u00f1os de experiencia con el tratamiento multimodal de la fase aguda de la enfermedad de Peyronie: Reporte m\u00e9dico de la vida real","volume":"43","author":"Gallo","year":"2019","journal-title":"Actas Urol. Esp. (Engl. Ed.)"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/andr.12927","article-title":"Medical, non-invasive, and minimally invasive treatment for Peyronie\u2019s disease: A systematic review","volume":"9","year":"2021","journal-title":"Andrology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4081\/aiua.2022.3.319","article-title":"Effects of long term sildena\ufb01l on the acute phase of Peyronie\u2019s disease in a combination treatment","volume":"94","author":"Topcuoglu","year":"2022","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e936146-1","DOI":"10.12659\/AJCR.936146","article-title":"Complete Plaque Regression in Patients with Peyronie\u2019s Disease After Multimodal Treatment with Antioxidants: A Report of 2 Cases","volume":"23","author":"Paulis","year":"2022","journal-title":"Am. J. Case Rep."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Paulis, G., and De Giorgio, G. (2022). Full Regression of Peyronie\u2019s Disease Plaque Following Combined Antioxidant Treatment: A Three-Case Report. Antioxidants, 11.","DOI":"10.3390\/antiox11091661"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s13256-022-03614-1","article-title":"Patients with Peyronie\u2019s disease achieve complete plaque regression after multimodal treatment with antioxidants: A case series","volume":"16","author":"Paulis","year":"2022","journal-title":"J. Med. Case Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/clinpract12060105","article-title":"Disappearance of Plaque Following Treatment with Antioxidants in Peyronie\u2019s Disease Patients-A Report of 3 Cases","volume":"12","author":"Paulis","year":"2022","journal-title":"Clin. Pract."},{"key":"ref_89","first-page":"12956","article-title":"Healing of Peyronie\u2019s disease after multimodal antioxidant treatment. A case series","volume":"96","author":"Paulis","year":"2024","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41443-022-00633-w","article-title":"A systematic review of non-surgical management in Peyronie\u2019s disease","volume":"35","author":"Hayat","year":"2023","journal-title":"Int. J. Impot. Res."},{"key":"ref_91","first-page":"41","article-title":"Controlled clinical trial of vitamin E in Peyronie\u2019s disease","volume":"9","author":"Pryor","year":"1983","journal-title":"Prog. Reprod. Biol. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1464-410x.2001.02241.x","article-title":"Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie\u2019s disease: A preliminary report","volume":"88","author":"Biagiotti","year":"2001","journal-title":"BJU Int."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1046\/j.1464-410X.2002.02738.x","article-title":"Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie\u2019s disease","volume":"89","author":"Cavallini","year":"2002","journal-title":"BJU Int."},{"key":"ref_94","first-page":"931","article-title":"Enfermedad de peyronie. Evaluaci\u00f3n de tres modalidades terap\u00e9uticas: Prop\u00f3leo, l\u00e1ser y prop\u00f3leo + l\u00e1ser [Peyronie\u2019s disease. Evaluation of 3 therapeutic modalities: Propoleum, laser and simultaneous propoleum-laser]","volume":"58","author":"Santana","year":"2005","journal-title":"Arch. Esp. Urol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.juro.2007.05.162","article-title":"Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie\u2019s disease: A double-blind, placebo controlled, randomized study","volume":"178","author":"Safarinejad","year":"2007","journal-title":"J. Urol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/ijir.2010.20","article-title":"Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie\u2019s disease: A double-blind, placebo-controlled randomized study","volume":"22","author":"Safarinejad","year":"2010","journal-title":"Int. J. Impot. Res."},{"key":"ref_97","first-page":"192","article-title":"Pharmacological therapy in patients diagnosed with Peyronie\u2019s disease","volume":"5","author":"Halal","year":"2012","journal-title":"J. Med. Life"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.2047-2927.2012.00007.x","article-title":"Efficacy of vitamin E in the conservative treatment of Peyronie\u2019s disease: Legend or reality? A controlled study of 70 cases","volume":"1","author":"Paulis","year":"2013","journal-title":"Andrology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1871528111312010009","article-title":"Peironimev-Plus\u00ae in the treatment of chronic inflammation of tunica albuginea (Peyronie\u2019s disease). results of a controlled study","volume":"12","author":"Paulis","year":"2013","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1871528112666131205112432","article-title":"Long-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin E and local diclofenac) on patients with Peyronie\u2019s disease (chronic inflammation of the tunica albuginea). Results of a controlled study","volume":"12","author":"Paulis","year":"2013","journal-title":"Allergy Drug Targets"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"E197","DOI":"10.5489\/cuaj.5255","article-title":"2018 Canadian Urological Association guideline for Peyronie\u2019s disease and congenital penile curvature","volume":"12","author":"Bella","year":"2018","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Cavallini, G., and Paulis, G. (2015). Combination therapy in the treatment of Peyronie\u2019s disease. Peyronie\u2019s Disease a Comprehensive Guide, Springer International Publishing. [1st ed.].","DOI":"10.1007\/978-3-319-17202-6"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13287-024-03761-w","article-title":"TGF-\u03b2 signaling regulates differentiation of MSCs in bone metabolism: Disputes among viewpoints","volume":"15","author":"Wei","year":"2024","journal-title":"Stem Cell Res. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.21037\/tau.2019.08.06","article-title":"Minimally invasive therapies for Peyronie\u2019s disease: The current state of the art","volume":"9","author":"Farrell","year":"2020","journal-title":"Transl. Androl. Urol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/bju.14784","article-title":"Optimizing collagenase Clostridium histolyticum therapy for Peyronie\u2019s disease using a novel approach with percutaneous needle tunnelling","volume":"124","author":"Angulo","year":"2019","journal-title":"BJU Int."},{"key":"ref_106","first-page":"655","article-title":"Peyronie\u2019s disease\u2014Watch out for the bend","volume":"46","author":"Love","year":"2017","journal-title":"Aust. Fam. Physician"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11934-014-0415-4","article-title":"Update on medical management of Peyronie\u2019s disease","volume":"15","author":"Tan","year":"2014","journal-title":"Curr. Urol. Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.aju.2013.03.008","article-title":"Peyronie\u2019s disease: A contemporary review of non-surgical treatment","volume":"11","author":"Levine","year":"2013","journal-title":"Arab J. Urol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ijir.2011.45","article-title":"Review of non-surgical treatment options for Peyronie\u2019s disease","volume":"24","author":"Larsen","year":"2012","journal-title":"Int. J. Impot. Res."},{"key":"ref_110","first-page":"26","article-title":"Intralesional Pentoxifylline Injection Versus Triamcinolone Acetonide in Treating localized Alopecia Areata: A Comparative Study","volume":"16","author":"Abdo","year":"2023","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5534\/wjmh.230016","article-title":"Medical Treatment for Peyronie\u2019s Disease: Systematic Review and Network Bayesian Meta-Analysis","volume":"42","author":"Lee","year":"2024","journal-title":"World J. Mens Health"}],"container-title":["Antioxidants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3921\/14\/2\/208\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:31:44Z","timestamp":1760027504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3921\/14\/2\/208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":111,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["antiox14020208"],"URL":"https:\/\/doi.org\/10.3390\/antiox14020208","relation":{},"ISSN":["2076-3921"],"issn-type":[{"value":"2076-3921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]}}}